Download full-text PDF

Source
http://dx.doi.org/10.1086/499112DOI Listing

Publication Analysis

Top Keywords

prevention laboratory-acquired
4
laboratory-acquired brucellosis
4
brucellosis side
4
side effects
4
effects prophylaxis
4
prevention
1
brucellosis
1
side
1
effects
1
prophylaxis
1

Similar Publications

Brucellosis is a zoonosis with non-specific clinical symptoms involving multiple systems and organs. Its prevalence is low in most of EU countries, which can lead to the difficulties in laboratory and clinical diagnostic. Due to its relationship to the Ochrobactrum spp.

View Article and Find Full Text PDF

Laboratory-acquired infection in clinical laboratories and the incidence rate after Brucella exposure risk events: a systematic review and meta-analysis.

J Hosp Infect

January 2025

Department of Hospital Infection Management, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address:

Background: Personnel in clinical microbiology laboratories face heightened risks of occupational infections, due to the potential for pathogenicity in clinical samples.

Aim: To summarize the characteristics of laboratory-acquired infections (LAIs) and review exposure incidents in clinical laboratories, and to conduct a meta-analysis to estimate post-exposure incidence rates and evaluate the efficacy of post-exposure prophylaxis (PEP) following Brucella exposures.

Methods: A systematic search across PubMed, Embase, Web of Science, CNKI, Wanfang, CMB, and the ABSA LAI database extracted relevant literature published from January 1, 1990, to August 31, 2023, including case reports and laboratory exposure risk events.

View Article and Find Full Text PDF

Current status of pathogen handling in European laboratories: focus on viral inactivation process.

Front Bioeng Biotechnol

June 2024

Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France.

For handling safely infectious agents, European laboratories must comply with specific EC Directives, national regulations and recommendations from the World Health Organization (WHO). To prevent laboratory acquired infections (LAIs) and pathogens dissemination, a key biosafety rule requires that any infectious material (clinical specimens or research samples) manipulated outside a biosafety cabinet (BSC) must be inactivated unless the lack of infectivity is proven. This inactivation process is a crucial step for biosafety and must be guided by a rigorous experimental qualification and validation procedure.

View Article and Find Full Text PDF

Management of unexpected laboratory exposure to Burkholderia pseudomallei.

Ann Biol Clin (Paris)

February 2024

Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France, Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Orsay, France.

Burkholderia pseudomallei is a Gram-negative saprophytic bacillus that causes melioidosis. The infection is endemic in South-East of Asia and Northern Australia. B.

View Article and Find Full Text PDF

Laboratory-acquired infections (LAIs) and accidental pathogen escape from laboratory settings (APELS) are major concerns for the community. A risk-based approach for pathogen research management within a standard biosafety management framework is recommended but is challenging due to reasons such as inconsistency in risk tolerance and perception. Here, we performed a scoping review using publicly available, peer-reviewed journal and media reports of LAIs and instances of APELS between 2000 and 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!